Weight Loss & Metabolic Peptides

Single, dual and triple receptor agonists · and the amylin axis

GLP-1 peptides are usually listed as one group and they form a ladder. The first rung binds one receptor. The second binds two. The third binds three, and a separate compound class acts on amylin receptors entirely. This page sets out which compound occupies which rung, what each additional receptor was added to address, and what the acylation and substitution chemistry behind their half-lives is doing.

Specification Table

Why Are GLP-1 Peptides Built as a Ladder?

Each rung exists because the rung below it left something on the table, and the sequence in which they were built explains the whole category.

Glucagon-like peptide-1 is an incretin, released from intestinal L-cells after a meal, acting at a class B G-protein coupled receptor.

A single agonist occupies that receptor alone. Semaglutide is the reference compound for this rung, and its published discovery paper sets out the two modifications that took the native peptide from a half-life of minutes to one measured in days.

Glucose-dependent insulinotropic polypeptide is the second incretin, acting at a separate receptor, and it had been considered a dead end for years because agonism at it alone produced little.

Tirzepatide put both activities into one molecule, and the published characterisation reports effects larger than the single agonist at matched exposure.

The third rung adds glucagon receptor agonism, which is counterintuitive since glucagon opposes insulin. The rationale in the literature is energy expenditure rather than glycaemic control, which is a different mechanism from the first two.

Retatrutide occupies that rung. Amylin sits outside the ladder entirely, acting at a distinct receptor complex, and cagrilintide is the compound in this range that addresses it.

So the category is not a set of interchangeable options. It is a design history, and knowing which rung a compound occupies tells you which published literature applies to it.

One caution about the ladder metaphor, which applies across all of the GLP-1 peptides in this range. Higher is not automatically better, since each added receptor brings its own biology and its own confounds into an experiment.

A study isolating one mechanism is better served by the compound that binds one receptor, and the triple agonist is the harder instrument to interpret rather than the more powerful one.

What Do the Half-Life Modifications Actually Do?

Two structural tricks recur across GLP-1 peptides, and both are visible in the sequence if you know what to look for.

The first is a substitution at position 2. Native GLP-1 carries an alanine there, and dipeptidyl peptidase-4 cleaves immediately after it, which is why the native peptide has a half-life of a couple of minutes.

Replacing that alanine with aminoisobutyric acid, a non-coded residue, obstructs the enzyme. The peptide is no longer a substrate it recognises.

The second is fatty acid acylation. A lipid chain is attached through a spacer to a lysine side chain, and the chain binds reversibly to circulating albumin.

Albumin is far too large for renal filtration, so bound compound is protected. The equilibrium then releases free peptide slowly, which converts a fast-clearing molecule into a slow-releasing depot without changing what it binds.

That is the entire basis of once-weekly dosing intervals reported in the published trials. It is chemistry rather than pharmacology.

For a researcher the practical consequence is that these two modifications are what a certificate has to confirm. A mass matching the unmodified sequence means the acylation is absent. The compound will behave nothing like the published material.

Asking whether the observed mass includes the fatty acid chain is therefore the single most useful verification question in this category.

What Does Chain Length Change Analytically?

These compounds are long by the standards of this catalogue, and length changes what a purity figure can tell you.

A bioregulator is two to four residues. A GLP-1 peptide is around thirty to forty. That is roughly a tenfold difference in synthesis steps.

Solid-phase synthesis couples one residue at a time, and every coupling has a yield below one hundred percent. Small inefficiencies compound across forty steps in a way they do not across three.

The dominant impurity class is therefore deletion sequences, molecules missing one internal residue, which are chemically very similar to the target and elute close to it.

Mass tells them apart in principle. In practice, a single missing residue on a forty-mer is often under two percent of total mass, which a nominal-resolution instrument cannot resolve from the parent.

High-resolution mass spectrometry does resolve it, and a certificate stating the instrument resolution is worth more here than one stating a purity percentage alone.

Chromatography carries more weight in this category for the same reason. A deletion sequence differs in hydrophobicity enough to shift retention, so the trace separates what the mass does not.

Where a supplier of GLP-1 peptides reports purity without a chromatogram and without stating resolution, the figure is not wrong so much as unable to answer the question that matters at this chain length.

How Does the Amylin Axis Differ?

One compound in this range is not an incretin at all, and grouping it with the ladder obscures what it is.

Amylin is co-secreted with insulin from pancreatic beta cells, and it acts at a receptor complex formed when the calcitonin receptor associates with receptor activity-modifying proteins.

That is a structurally different target from the class B receptors the incretin compounds bind, and the downstream signalling is not the same.

Cagrilintide is the amylin analogue stocked here. Native amylin is prone to aggregation into insoluble fibrils, which is the practical reason the native peptide was never a workable research article.

The analogue carries substitutions that suppress that aggregation, which is a formulation problem solved by sequence design rather than by buffer.

That matters for handling. An amylin analogue is more aggregation-prone in solution than an incretin peptide of similar length, so concentration and temperature are less forgiving.

Where cagrilintide appears alongside an incretin compound in the same study, the two are acting through separate receptor systems, and any combined effect is an interaction rather than an addition.

Published work on the combination reports it as such, and reading it as a single mechanism misstates what was measured.

Storage for the amylin analogue therefore departs from the rest of the category. Aliquot on first reconstitution rather than returning a single vial to the freezer repeatedly, and keep working concentrations toward the lower end of what the assay tolerates.

Aggregation is largely irreversible once it starts, so the precaution is worth more than any recovery step available afterwards.

What Should Be Verified Before Ordering?

Six checks cover this category, and three of them are specific to compounds of this length and this modification pattern.

Whether the observed mass includes the fatty acid chain, which distinguishes the intended compound from unacylated peptide of the same sequence.

Whether the position 2 residue is the non-coded substitution rather than alanine, since the unmodified peptide is a different molecule with a half-life two orders of magnitude shorter.

The instrument resolution used for the mass determination, because at this chain length a single deletion is within the error of a nominal-mass measurement.

The chromatogram rather than the purity number, since deletion sequences are the dominant impurity and they resolve chromatographically where they may not resolve by mass.

Counterion and net peptide content, which apply here as everywhere, though the proportional correction is smaller for a forty-mer than for a dipeptide.

Storage history, since these compounds are supplied lyophilized and are stable dry, while in solution they aggregate over time in a concentration-dependent way.

Reconstituted material in this category should be aliquoted rather than repeatedly thawed, because freeze-thaw cycling drives the aggregation that the sequence design was intended to suppress.

A supplier who can answer the acylation question and the resolution question has done the analysis. One who cannot has bought powder and printed a label.

One further point applies to the whole ladder rather than to any single rung. Because these compounds differ from one another by only a few residues in some cases, a certificate naming the product without stating the sequence has not distinguished it from its neighbours.

Semaglutide and the dual agonist share substantial sequence identity, and a mass alone will not always separate them cleanly at nominal resolution.

Asking for the sequence in single-letter form alongside the mass costs a supplier nothing and settles the question outright.

Which GLP-1 Medications Are Approved, and Under What Names?

This is the part of the category that matters most, because almost every compound named here has an approved counterpart and the two are not the same product.

Semaglutide is approved as Ozempic for type 2 diabetes, as Wegovy for weight management, and as Rybelsus in an oral form for type 2 diabetes as well.

Tirzepatide is approved as Mounjaro for type 2 diabetes and as Zepbound for weight management. It is a dual agonist, hitting the GLP-1 receptor and the receptor for gastric inhibitory polypeptide.

Liraglutide is Victoza and Saxenda, dulaglutide is Trulicity, exenatide was Byetta and Bydureon, lixisenatide was Adlyxin, and albiglutide was withdrawn from the market.

Exenatide is worth a line of its own, since it is a synthetic version of exendin-4, a peptide from Gila monster venom, and it is where this whole drug class started.

Exendin-4 resists the enzyme that clears native GLP-1 within minutes, which is why exenatide worked as a drug when the human hormone could not, and the GLP-1 analogs that followed each solved that problem in their own way.

Those GLP-1 medications differ mainly in how they achieve that, and the differences between GLP-1 agonists are pharmacokinetic before they are pharmacological.

Every one of those type 2 diabetes approvals rests on glycaemic and cardiovascular outcome data, and the weight indications rest on separate trials again.

Fat loss specifically, as distinct from total weight loss, is the endpoint the newer body composition work is trying to isolate.

Those approvals rest on large cardiovascular and weight outcome trials. They are the reason GLP-1 therapy is prescribed at all, and they belong to the finished products rather than to the molecules in the abstract.

Retatrutide is the triple agonist still in late-stage trials and holds no approval anywhere.

Research-grade material is not any of those products. It has not been through the manufacturing controls those approvals require, and no research preparation carries their evidence.

What Is the Position on Compounded GLP-1 Peptides?

This changed recently enough that a great deal of published guidance is now out of date, so it is worth stating the current position plainly.

Compounding pharmacies were permitted to prepare semaglutide and tirzepatide while those drugs sat on the FDA drug shortage list, because shortage status opens a specific legal exemption.

The FDA declared both shortages resolved, which closed that exemption. Compounded semaglutide and tirzepatide are no longer lawfully available on that basis in the United States.

Compounded peptides of this kind continue to circulate regardless, and the FDA has issued warnings about dosing errors with them, several involving overdoses from unfamiliar syringe measurements.

Salt forms are the other documented problem. Semaglutide sodium and semaglutide acetate are not the same substance as the approved base, and the FDA has stated they are not suitable for compounding.

Any research material sold in this category is a further step removed again, being neither an approved product nor a compounded preparation dispensed against a prescription.

What Do These Compounds Actually Do?

The mechanism is well characterised, which distinguishes this category from most of the catalogue.

GLP-1 is an incretin hormone released from the gut after eating, cleaved from preproglucagon, and the active fragment is usually written GLP-1 (7-37).

It acts on pancreatic beta-cells to drive glucose-dependent insulin secretion, and that glucose dependence is why insulin release rises after a meal rather than continuously.

Those pancreatic β-cells sit in the pancreas alongside the alpha-cells the same hormone suppresses, which is how one signal moves glucose handling in two directions at once.

Peptide hormones of this kind are built from short chains of amino acids and are cleared quickly by design, since a hormone that persisted would defeat the regulation it exists to provide.

Energy balance and metabolic homeostasis are the framings used for that regulation across the incretin literature, and fat metabolism follows from them rather than being targeted directly.

It suppresses glucagon secretion from the same organ, slows gastric emptying, and acts centrally to increase satiety and reduce appetite.

Signalling runs through a class B G-protein coupled receptor into cAMP, and those signaling molecules are the same across the incretin hormones generally.

Slowed gastric emptying and central satiety together account for most of the reported weight loss, and reduced cravings is how patients usually describe it.

Effects on blood sugar, insulin sensitivity and insulin resistance follow from the pancreatic arm, and improvements in blood pressure and lipids were reported in the outcome trials.

Reported effects on body composition are the contested part. Weight loss on these drugs includes lean mass as well as fat loss, and preserving lean muscle is why resistance training is advised alongside them.

Muscle preservation is an active research question rather than a settled one, and it is why amylin analogues and myostatin-directed compounds are being studied as combination partners.

Body composition after substantial weight loss is measured rather than assumed in the better trials, and body composition change is where the class attracts most of its current criticism.

Effects on obesity as a clinical condition are what the weight indications rest on, and obesity trial populations were selected by BMI rather than by appearance.

Sex differences in response, including the role of estrogen in fat distribution, are under study and not established.

What Is the Documented Safety Profile?

These are among the best-characterised compounds in this catalogue, so the risks are known rather than speculative.

Gastrointestinal effects dominate. Nausea, vomiting, diarrhoea and constipation are common, dose-related, and the usual reason people stop.

Pancreatitis appears in the labelling for the class, and gallbladder disease including gallstones is reported, both plausibly linked to rapid weight loss as well as to the drugs themselves.

Hypoglycemia is uncommon with a GLP-1 agonist alone, because insulin secretion is glucose-dependent, and becomes a real risk in combination with insulin or a sulfonylurea.

Thyroid C-cell tumours in rodents produced a boxed warning covering personal or family history of medullary thyroid carcinoma and MEN 2.

These are not indicated in type 1 diabetes, and the cardiovascular events data that supports them was gathered in specific trial populations rather than in general use.

All of that describes approved products at approved doses under supervision, with a BMI or HbA1c threshold governing who receives them.

Nothing supplied as a research chemical carries that supervision, and metabolic dysfunction is a clinical problem requiring a clinician rather than a purchase.

Compounds such as BPC-157, CJC-1295/ipamorelin and 5-Amino-1MQ appear in the same clinic menus for metabolic health and share no mechanism with the incretin axis.

Reported effects on sleep quality, chronic inflammation, cognitive function and tissue repair are secondary observations from those trials rather than indications.

Material in this category is supplied for laboratory research only and is not for administration to humans or animals.

Published Literature

Selected references on the receptor pharmacology and on the modification chemistry behind the half-lives.

1. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. https://doi.org/10.1016/j.cmet.2018.03.001
2. Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 analog semaglutide. J Med Chem. 2015;58(18):7370-7380. https://doi.org/10.1021/acs.jmedchem.5b00726
3. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist. Mol Metab. 2018;18:3-14. https://doi.org/10.1016/j.molmet.2018.09.009
4. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155. https://doi.org/10.3389/fendo.2019.00155

Frequently Asked Questions